公开(公告)号：US20220135668A1

公开(公告)日：2022-05-05

申请号：US17574980

申请日：2022-01-13

Applicant: AMGEN INC.

Inventor： John P. Gibbs, II ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24 ,  A61K39/00

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.

公开(公告)号：US20200277368A1

公开(公告)日：2020-09-03

申请号：US16598714

申请日：2019-10-10

Applicant: AMGEN INC.

Inventor： John P. Gibbs, II ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.